Chromocell Therapeutics Corp Quarterly Operating Income (Loss) in USD from Q1 2023 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Chromocell Therapeutics Corp quarterly/annual Operating Income (Loss) history and growth rate from Q1 2023 to Q2 2024.
  • Chromocell Therapeutics Corp Operating Income (Loss) for the quarter ending June 30, 2024 was -$1.76M, a 127% decline year-over-year.
  • Chromocell Therapeutics Corp annual Operating Income (Loss) for 2023 was -$6.86M, a 196% decline from 2022.
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$1.76M -$987K -127% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-13
Q1 2024 -$1.93M -$1.02M -111% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q2 2023 -$777K Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 -$915K Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.